The financials are screaming an uptrend in sales, NO LONG TERM DEBT (for a long time up to date) and profits ahead.
And only a real company gets a debt facility like the one they just got. Just saying...
And here is where the Ex-CoCEO Elena Polyakova has been for the past couple of years: In Singapore
August 17, 2020 – Ronkonkoma, NY – G6 Materials Corp. (TSXV: GGG, OTCQB: GPHBF) (“G6” or the “Company”) is pleased to announce that its has finalized the research and development project to develop graphene-based composite materials for marine vessel applications (the “Project”) with a private Singaporean company (“Partner”). The Partner has accepted G6’s final research report and the Company expects to receive a final payment from the Partner of approximately $117,500 US Dollars, or $161,400 Singapore Dollars. During the Project, G6 successfully developed two formulations for graphene-enhanced resins for fiberglass and carbon fiber marine composites.
Should show in the net Q maybe??? Just a hint...
According to various test results, the graphene-enhanced formulations demonstrated tangible advancements compared to conventional materials. In addition to the improved strength of the resin, the graphene-enhanced epoxy shows a 14-fold improvement of the fracture toughness. The new material exhibited 20% less water absorption and the fiberglass composite’s fatigue resistance was increased 3-fold, thereby making the service life of the new material longer than other formulations currently used in industry. The developed formulations were subject to extensive testing done in the Company’s lab, through third-party performance evaluation of the composite materials as well as via field testing conducted at the Lungteh Shipbulding shipyard.
This concludes a two-year research effort to develop graphene-enhanced marine composites. “We are very happy that this research project has come to a successful conclusion. We have developed materials with superb performance and are eager to start offering them to our customers,” said Daniel Stolyarov, President & CEO of G6. “Not only can the marine industry benefit from using these graphene-enhanced formulations, but these materials can also be used for applications in the construction, automotive and green energy industries,” added Mr. Stolyarov.
Pursuant to the agreement between G6 and the Partner, the intellectual property rights will remain with the Partner while the Company has a non-exclusive license to use the formulations for commercial purposes. The Partner is entitled to a four per cent royalty on the sales of the materials generated by the Company, subject to the final use of the materials being in the field of marine vessels or marine structures (the “Field of Use”). The Company is free to sell the materials without making any royalty payments outside of the Field of Use. The Company and the Partner are exploring the possibility of building a prototype boat to evaluate the performance of the materials in a real-life environment.
October 1st, 2020
G6 Materials Reports 2020 Annual Financial Results Results feature record quarterly revenues in 4Q20, which increased by 2.4x over 3Q20
Financial Highlights
? Revenue for the fourth quarter ended May 31, 2020 reached a record level of $406,684, which is a 2.4x increase from the $169,237 reported for the third quarter of 2020 and a 2.0x increase from the $206,609 reported for the same period of the prior year ?
? Revenue for the year ended May 31, 2020 was $922,614, which is similar to the $946,834 reported in the previous fiscal year ?
? Comprehensive loss for the fourth quarter ended May 31, 2020 was $251,168, a 11% increase from the $226,213 reported for the third quarter of 2020 and a 248% increase from the $72,212 reported for the same period of 2019 ?
? Comprehensive loss for the year ended May 31, 2020 was $1,002,112, a 69% increase from the $601,565 reported for the same period of 2019 ?
? Total assets for the year ended May 31, 2020 increased by 9% to $1,165,686 from $1,066,851 for the same period of last year
?
Corporate Highlights
? Marine Composite Project: As previously announced, the Company entered into a research agreement with a Singapore-based firm to develop a graphene composite for marine vessels. This project was mostly completed in the fiscal year of 2020, which the Company reported as complete in August of 2020. While working on this project, the Company developed two composite formulations using graphene additives with carbon fiber and fiberglass that provide a 14-fold improvement of fracture toughness and a 3-fold improvement of fatigue resistance. These results were reported in an event at Capitol Hill (Washington DC, USA) and at the TechConnect World Innovation Expo. Detailed technical specifications can be found at the Company’s web site.
? Pharma Project: In October of 2019, the Company was granted a patent from US Patent Office for its proprietary technology involving the synthesis of trifluoroketones, which serves as a key intermediate step in the synthesis of a drug under development by the Company’s pharmaceutical industry partner. This drug is being tested for the treatment of certain lung conditions and, in June of 2020, the Company signed a licensing agreement with its partner. According to the terms of this agreement, in exchange for a US$220,000 payment the Company is providing a 2-year exclusive license and an option to purchase the IP rights for a fixed price of US$1,000,000. ?
? Air Purification Project: In the last quarter of the fiscal year, to address the demand for air purification products as a result of the global coronavirus pandemic the Company added a line of existing air purification products to its portfolio. Further, the Company’s research and development team developed a graphene-based technology to create an enhanced air filtration system. Subsequently, a provisional patent application was filed to protect the IP rights for this technology.
Outlook
Despite the global COVID-19 pandemic presenting society with numerous challenges in 2020, it has also created opportunities to identify areas for improvement, apply new technologies and make permanent advancements for the future. Based on G6’s recent success in selling air filtration and purification products to meet a surge in demand, the Company has continued to allocate resources in pursuit of this market opportunity. Management expects this positive trend to continue into the 2021 fiscal year and is working to develop a new line of proprietary, graphene-based, air filtration products to launch into the market. In parallel, G6 will continue to sell its legacy product lines and strengthen its portfolio of intellectual property through further research and development.
According to the 1Q21 results report, they are telling the truth. An uptrend in sales is evident.
November 2, 2020
G6 Materials Reports Record 1Q21 Financial Results Highest Quarterly Revenues Since Inception plus Positive Comprehensive Income
Financial Highlights (all amounts expressed in US Dollars unless otherwise noted)
? Revenue for the first quarter ended August 31, 2020 reached a record level of $1,169,426, which is a 188% increase from the $406,684 reported for the fourth quarter of 2020 and a 497% increase from the $195,928 reported for the same period of the prior year, which was primarily due to strong customer demand for the Company’s air purification products and the receipt of a one-time payment as per the terms of a license and option agreement ?
? Gross profit for the first quarter ended August 31, 2020 was $426,608, a 925% increase from the $41,625 reported for the fourth quarter of 2020 and a 481% increase from the $73,469 reported for the same period of the prior year, which was also primarily due to strong customer demand for the Company’s air purification products and the receipt of a one-time payment as per the terms of a license and option agreement ?
? Comprehensive income for the first quarter ended August 31, 2020 was $110,765, as compared to the $251,168 comprehensive loss reported for the fourth quarter of 2020 and the $180,735 comprehensive loss reported for the same period of 2019, which was primarily due to reduced expenses in the areas of research and development as well as lower general and administration expenses from cost-saving initiatives ?
? Total assets for the first quarter ended August 31, 2020 increased by 26% to $1,472,872 from $1,165,686 for the fourth quarter of 2020 and a 39% increase from $1,057,297 for the same period of last year ?
Management Commentary
?“The first fiscal quarter of 2021 was a significant milestone for G6 as we generated our best financial results in the history of the Company. Overcoming the challenges of early 2020, strategically pivoting the business and successfully capitalizing on a new market opportunity are all key accomplishments as G6 continues to evolve and grow,” said Daniel Stolyarov, President & ?CEO of G6 Materials Corp. “I would like to express my appreciation for the great efforts of our team to achieve these record quarterly results, as well as my gratitude to all customers who purchased our air purification products. We are excited to bring graphene-enhanced air filtration products to market and further commercialize G6’s intellectual property in this area,” added Mr. Stolyarov.
Corporate Highlights (all amounts expressed in US Dollars unless otherwise noted)
? Air Purification Products: In the second half of the 2020 fiscal year, the Company added a line of existing air purification products to its portfolio to address the step-change in demand for air purification products primarily as the result of the global coronavirus pandemic. The sale of these products accelerated significantly during the first quarter of the 2021 fiscal year, which is evident in the Company’s financial results. Further, the Company’s research and development team developed a graphene-based technology for an enhanced air filtration system for which a provisional patent application was filed to protect the intellectual property rights. ?
? License and Option Agreement: On June 23, 2020, the Company entered into a License and Option Agreement with a US-based clinical-stage biopharmaceutical company. As per the agreement, the Company received a one-time cash payment of $220,000 by granting the partner an exclusive license to use the intellectual property for a period of two years. Further, the partner will also have an option to purchase the Company’s intellectual property rights for an incremental $1,000,000 during the license period.
? Debt Facility: The Company has entered into a loan agreement with an arm’s length third- party company, pursuant to which G6 can now draw up to an aggregate principal amount of $1,000,000 on an unsecured basis for a one-year term. Any principal amounts drawn under the facility will accrue interest at a rate of 5.0% per year. The loan can be used for general working capital purposes.
The company has operated without any long term or toxic debt for a while and their cash raises are directly performed without extra expenses. No unnecessary diluting seen for the past 5 years or as far as I can see. MG&A expenses have been under control. Take a look for the past 3 years.
